YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Dianthus Therapeutics (DNTH) has moved into the capital markets spotlight after filing a US$500 million follow on equity offering of common stock alongside a broad universal shelf registration. The capital raise comes after a sharp pullbac…
On August 4, Dianthus Therapeutics (NASDAQ:DNTH) reported second-quarter 2026 results alongside a stack of pipeline updates that touched nearly every program the company runs. For a clinical-stage biotech with no approved product yet, the…
[Wall Street NY] Nikada/E+ via Getty Images Citi on Friday issued a new Buy rating on Dianthus Therapeutics (DNTH [https://seekingalpha.com/symbol/DNTH]), a biotech developing drugs for autoimmune conditions, citing a multibillion-dollar p…
UiPath downgraded, Shell upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by…
Dianthus Therapeutics, Inc. NEW YORK and WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform t…
Key Points iShares Global Healthcare ETF offers a 1.4% dividend yield and lower price volatility than State Street SPDR S&P Biotech ETF. State Street SPDR S&P Biotech ETF focuses on U.S. biotechnology, resulting in a higher 1-year total re…
Investors choosing between iShares Global Healthcare ETF (NYSEMKT:IXJ) and State Street SPDR S&P Biotech ETF (NYSEMKT:XBI) must weigh the high-growth potential of specialized U.S. biotech against a more stable, dividend-paying global healt…
NEW YORK and WALTHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoim…
Key Points State Street Health Care Select Sector SPDR ETF provides a much lower expense ratio of 0.08% compared to the 0.35% for State Street SPDR S&P Biotech ETF. State Street Health Care Select Sector SPDR ETF offers a higher trailing-1…
While State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) offers broad exposure to established healthcare giants at a minimal cost, State Street SPDR S&P Biotech ETF (NYSEMKT:XBI) provides a more volatile, equal-weighted focus on…
The growth of the chronic inflammatory demyelinating polyneuropathy market is expected to be primarily driven by an expanding diagnosed patient population, improved disease awareness and diagnostic rates, increasing treatment uptake of imm…
Shares of Dianthus Therapeutics DNTH have surged 88.9% over the past six months against the industry's 2.9% decline, fueled by growing investor confidence in the commercial potential of its lead asset, claseprubart (DNTH103), and multiple…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Dianthus Therapeutics reported a 75% response rate in a late-stage trial of claseprubart in CIDP. The update comes shortly a…
The S&P 500 Index ($SPX) (SPY) on Wednesday closed down -1.62%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -1.87%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -1.98%. June E-mini S&P futures (ESM26) fell -1.62%, and…
The S&P 500 Index ($SPX) (SPY) on Wednesday closed down -1.62%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -1.87%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -1.98%. June E-mini S&P futures (ESM26) fell -1.62%, and…
The S&P 500 Index ($SPX) (SPY) today is down -0.61%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.88%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.80%. June E-mini S&P futures (ESM26) are down -0.71%, and June E-mini Nas…
The S&P 500 Index ($SPX) (SPY) today is down -0.28%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.38%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.28%. June E-mini S&P futures (ESM26) are down -0.25%, and June E-mini Nas…
The S&P 500 Index ($SPX) (SPY) today is down -0.61%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.88%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.80%. June E-mini S&P futures (ESM26) are down -0.71%, and June E-mini Nas…
Sanofi scrapped a final-phase study Wednesday of an experimental CIDP treatment. The stock tumbled in response. Continue Reading
The S&P 500 Index ($SPX) (SPY) today is down -0.28%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.38%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.28%. June E-mini S&P futures (ESM26) are down -0.25%, and June E-mini Nas…
The targeted oncology sector is shifting after GSK (GSK [https://seekingalpha.com/symbol/GSK]) decided to buy [https://seekingalpha.com/news/4601644-gsk-to-buy-nuvalent-for-106b] Nuvalent (NUVL [https://seekingalpha.com/symbol/NUVL]) for $…
Dianthus Therapeutics Inc. (NASDAQ:DNTH) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 7, Raymond James increased its price target on Dianthus Therapeutics Inc. (NASDAQ:DNTH) from $123 to $125.…
Octagon Capital Advisors cut its stake in Dianthus Therapeutics(NASDAQ:DNTH) by 470,000 shares, an estimated $27.22 million trade based on quarterly average pricing, according to a May 15, 2026 SEC filing. What happened According to a SEC…
On May 15, 2026, Cormorant Asset Management disclosed a new position in Dianthus Therapeutics(NASDAQ:DNTH), acquiring 950,000 shares in an estimated $55.01 million trade based on quarterly average pricing. What happened According to a Secu…
Key Points Avidity Partners added 259,700 shares of Enliven Therapeutics in the first quarter; the estimated transaction value was $7.19 million (based on quarterly average pricing). The quarter-end position value increased by $14.33 milli…
Avidity Partners Management disclosed a buy of 259,700 shares of Enliven Therapeutics(NASDAQ:ELVN) in its May 13, 2026, SEC filing, an estimated $7.19 million transaction based on quarterly average pricing. What happened According to a SEC…
On May 13, 2026, Avidity Partners Management disclosed a new position in Aktis Oncology(NASDAQ:AKTS), acquiring 468,566 shares in the first quarter. The estimated transaction value was $9.10 million based on quarterly average pricing. What…
NANJING, China, May 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; Stock Code: 9887.HK) today announced that its partner, Dianthus Therapeutics, Inc. (“Dianthus”; NASDAQ: DNTH), has selected Sjögren's diseas…
NEW YORK and WALTHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimm…
On April 9, 2026, Dianthus Therapeutics(NASDAQ:DNTH) Executive Vice President, Chief Financial Officer, and Chief Business Officer Ryan Savitz reported the sale of 8,224 shares of common stock for total proceeds of approximately $739,000,…
Key Points 8,224 shares (~$739,000) of common stock were sold on April 9, 2026, at a weighted average price of around $89.84 per share. This transaction represented 100.00% of Mr. Savitz's direct common stock holdings, reducing his direct…
NEW YORK and WALTHAM, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoi…
Ryan Savitz, executive vice president, chief financial officer, and chief business officer of Dianthus Therapeutics (NASDAQ:DNTH), reported the sale of 114,367 shares of common stock for approximately $9.49 million via open-market disposit…
Key Points 114,367 shares were sold for a transaction value of approximately $9.49 million on March 31, 2026. The transaction represented 100% of Savitz's direct common stock holdings, reducing direct ownership of this class to zero. This…
[FDA Headquarters] Shares of Dianthus Therapeutics (DNTH [https://seekingalpha.com/symbol/DNTH]) spiked on Thursday after the company announced that the FDA agreed with several proposed changes related to clinical development of its lead c…
We recently compiled a list of the Top 10 Boring Stocks That Make Money. Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is among the most boring stocks. TheFly reported on March 12 that Wedbush raised its price target on DNTH to $103 from $80 w…